From Nasdaq: 2025-06-12 16:43:00

The Zacks Research Daily highlights new reports on 16 major stocks, including Microsoft Corp. (MSFT), AstraZeneca PLC (AZN), and BlackRock, Inc. (BLK), along with micro-cap stocks Taylor Devices, Inc. (TAYD) and Geospace Technologies Corp. (GEOS). The microcap research on these small companies is unique and exclusive to Zacks, providing valuable insights for investors.

Microsoft’s shares have shown an 8.5% gain over the past year, driven by AI business momentum, Azure cloud expansion, and strong Office 365 Commercial demand. The company expects a 13.7% increase in net sales for fiscal 2025, although concerns remain around elevated operating expenses and heightened cloud competition.

AstraZeneca’s diverse product portfolio and global footprint have led to a 13.9% outperformance in the Medical – Biomedical and Genetics industry. Key drugs like Lynparza and strategic collaborations are driving revenue growth, with strong pipeline data lined up. However, potential challenges in China and ongoing investigations pose risks for the company’s top line.

BlackRock’s shares have outperformed the Financial – Investment Management industry with a 31.2% gain. The company’s expansion strategy and product diversification efforts are expected to drive revenue and assets under management growth. However, elevated expenses and geopolitical tensions remain as headwinds, affecting profitability and sustainability.

Taylor Devices, Inc. has faced challenges in the General Industrial industry, with a 17.1% decline in share value. Despite execution inefficiencies and increased SG&A burdens, the company maintains financial resilience with a debt-free balance sheet and growing international sales. Geographic diversification and a focus on long-term contracts are supporting revenue stability.

Geospace Technologies Corp. has struggled in the Measuring Instruments industry, with a 29.4% decline in shares. Challenges in Energy Solutions and rising costs are offset by growth in Smart Water segment revenue. The company’s strong balance sheet and strategic initiatives support R&D and growth opportunities, offering potential value for investors.



Read more at Nasdaq: Top Stock Reports for Microsoft, AstraZeneca & BlackRock